2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Bin Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs D, Ravi P, Hussain S, Murad M, Boorjian S, Sweeney C, Van Allen E, Bryce A. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology 2023, 9: 635-645. PMID: 36862387, PMCID: PMC9982744, DOI: 10.1001/jamaoncol.2022.7762.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerAndrogen pathway inhibitorsSystemic treatment optionsProgression-free survivalOverall survivalTreatment optionsClinical trialsTriplet therapyProstate cancerFirst-line systemic treatment optionComparative effectivenessFirst-line treatment optionHigh-volume diseaseHigher adverse eventsImproved overall survivalLow-volume diseaseHealth-related qualityFuture clinical trialsDifferent treatment optionsHeterogeneous patient populationVolume of diseaseOutcomes of interestTriplet regimensEligible RCTs
2021
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Riaz I, Fuentes H, Naqvi S, He H, Sipra Q, Tafur A, Padranos L, Wysokinski W, Marshall A, Vandvik P, Montori V, Bryce A, Liu H, Badgett R, Murad M, McBane R. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings 2021, 97: 308-324. PMID: 34172290, DOI: 10.1016/j.mayocp.2020.10.041.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsCancer-associated thrombosisTreatment of CATMajor bleedingSystematic reviewOral anticoagulantsRecurrent venous thromboembolism (VTE) eventsRelevant nonmajor bleedingUse of apixabanVenous thromboembolism eventsNetwork Meta-AnalysisStandard of careDifferent treatment optionsMixed treatment comparisonNonmajor bleedingThromboembolism eventsVTE recurrenceControlled TrialsWeight heparinTreatment optionsDalteparinHigh riskCurrent evidenceBleedingMeta-Analysis